Key Highlights

  • Clarivate closed the sale of its LS&H segment to Altaris on October 6.
  • The $600 million deal is intended to reduce debt.
  • Second-quarter revenue was $587.3 million, with a $268.6 million net loss.
  • Updated guidance is due with third-quarter results on November 3.

Clarivate Plc (NYSE:CLVT), the information-services group behind Web of Science and Derwent, is in focus after completing the sale of its Life Sciences & Healthcare (LS&H) segment to Altaris, LLC on October 6. The deal, valued at $600 million, reshapes the company into two segments and is intended to cut debt. The next scheduled catalyst is third-quarter reporting on November 3, when management has said it will update its full-year guidance.

Latest Company Context

The sale was first announced on July 6, 2026 and closed on October 6. Clarivate said it intends to use the proceeds to reduce debt and strengthen its balance sheet. The remaining businesses are Academia & Government (Web of Science, ProQuest, Alma, Vega) and Intellectual Property (IPOne, Derwent, CompuMark, IPfolio). In its second-quarter report on July 29, Clarivate posted revenue of $587.3 million, down from $621.4 million, with organic revenue down 1.5%; adjusted EBITDA of $247.2 million (42.1% margin); adjusted diluted EPS of $0.19; and a net loss of $268.6 million after a $221.7 million non-cash goodwill impairment. Total debt was $4,251.5 million at June 30, versus a year earlier lower by $218.4 million, and cash was $217.7 million. The release also showed first-half free cash flow of $122.9 million.

Key Business Drivers

Management guidance, reaffirmed on July 29 before the sale closed, called for 2026 adjusted EBITDA of $980 million to $1.04 billion, adjusted EPS of $0.70 to $0.80 and free cash flow of $365 million to $435 million, including LS&H. Those figures will change, as the company has said it will update guidance for the divestiture, and LS&H had weaker organic trends (revenue down 5.2% organic in Q2). Debt reduction is the central theme: $600 million is meaningful against about $4.25 billion of debt, though the exact amount applied has not been disclosed. Lower interest costs could aid earnings, while lost EBITDA from LS&H partially offsets this. Transactional revenue, down 15.7% organically in Q2, remains a soft spot.

What Investors Should Watch

The November 3 third-quarter release and the revised 2026 outlook are the key events. Investors may watch for how much debt is repaid, any cash tender offers or refinancing, leverage ratios, and whether buybacks resume after reduced first-half repurchases of $18.1 million. Organic recurring revenue and annual contract value trends, progress on the company's AI roadmap, and Intellectual Property segment performance (organic revenue down 2.3% in Q2) are other indicators.

From Announcing to Completing a Major Portfolio Change

Clarivate has moved from announcing to completing a major portfolio change. The $600 million sale and its debt-reduction aim set the stage, with updated guidance on November 3 revealing the post-sale financial profile.